Salud financiera de hoja de balance de Astellas Pharma

Salud financiera controles de criterios 4/6

Astellas Pharma tiene un patrimonio de accionistas total de ¥1,529.8B y una deuda total de ¥935.8B, lo que sitúa su ratio deuda-patrimonio en 61.2%. Sus activos y pasivos totales son ¥3,462.2B y ¥1,932.4B respectivamente. El BAIT de Astellas Pharma es de ¥170.0B, por lo que su ratio de cobertura de intereses es de 38.6. Tiene efectivo e inversiones a corto plazo que ascienden a ¥293.0B.

Información clave

61.2%

Ratio deuda-patrimonio

JP¥935.83b

Deuda

Ratio de cobertura de intereses	38.6x
Efectivo	JP¥292.99b
Patrimonio	JP¥1.53t
Total pasivo	JP¥1.93t
Activos totales	JP¥3.46t

Actualizaciones recientes sobre salud financiera

Is Astellas Pharma (TSE:4503) A Risky Investment?

Jun 14

Recent updates

Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Nov 06

Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think

Nov 01

Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors

Oct 15

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 24

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 03

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Aug 20

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 26

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 29

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Feb 29

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (¥1,203.0B) de 4503 superan a sus pasivos a corto plazo (¥1,093.4B).

Pasivo a largo plazo: Los activos a corto plazo de 4503 (¥1,203.0B) superan a sus pasivos a largo plazo (¥839.0B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 4503 (42%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 4503 ha crecido de 0.2% a 61.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de 4503 está bien cubierta por el flujo de caja operativo (21.5%).

Cobertura de intereses: Los pagos de intereses de la deuda de 4503 están bien cubiertos por el BAIT (38.6x cobertura).

Salud financiera de hoja de balance de Astellas Pharma

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Astellas Pharma (TSE:4503) A Risky Investment?

Recent updates

Consensus EPS estimates increase by 40%

Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Consensus EPS estimates fall by 35%

Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 11%

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Upcoming dividend of JP¥37.00 per share

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 21%

Consensus EPS estimates fall by 15%

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Consensus EPS estimates fall by 16%

Final dividend of JP¥37.00 announced

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Astellas Pharma (TSE:4503) A Risky Investment?

Consensus EPS estimates fall by 11%

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Consensus EPS estimates fall by 16%

Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Consensus EPS estimates fall by 14%

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Upcoming dividend of JP¥35.00 per share

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Consensus EPS estimates fall by 11%

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

New minor risk - Profit margin trend

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Upcoming dividend of JP¥35.00 per share at 3.3% yield

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer